Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer Webinar #1 (2017)
Complimentary Educational Series. Registration is required and is FREE to all registrants!
- Webinar 1: Immunotherapy: From Research to Practice
- Webinar 2: Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer
- Webinar 3: AUA New Muscle Invasive Bladder Cancer Guideline
- Webinar 4: Complex Patient Cases in Bladder Cancer
The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
The initiative is comprised of five unique activities, including four live webinars and an online, interactive, case-study activity. Each live webinar will be offered as a live webinar twice and then again as a webcast and podcast so that you can participate at a time and location that works best for you. Each live webinar will offer interactive discussion along with Q&A and audience participation.
The goal of this knowledge-based activity is to improve clinicians’ understanding of the relevance of immunotherapy and to increase their confidence in the clinical application of these therapies based on current evidence.
This educational series is supported by independent educational grants from:
- Bristol-Myers Squibb
- Non-Urologist MD
At the conclusion of this activity, the learner will be able to:
- Restate the role of the immune system in cancer prevention and elimination.
- Explain the function of the PD-1 and CTLA-4 pathways in the suppression of T cell activity.
- Discuss the effects of immune system checkpoint inhibitors on the immunosuppressive activity of tumor cells.
- Recognize the antitumor effects of currently available immune system checkpoint inhibitors in solid tumors.
Robert S. Svatek, MD, MSCI
Department of Urology
UT Health Science Center at San Antonio
Joshua J. Meeks, MD, PhD
Associate Professor of Urology
|Name||Faculty Role||Company||COI Role||Financial||Date Disclosed|
|Joshua J. Meeks, MD, PHD||Faculty|
National Comprehensive Cancer Network- Prostate Cancer Guidelines Committee
Scientific Study or Trial
|Robert S. Svatek, MD||Director|
Consultant or Advisor
Consultant or Advisor
Consultant or Advisor
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this internet live activity and enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation